Changes in renal function after changes in antifungal drug therapy

American Journal of Health-System Pharmacy

Volumn 61, Issue 1, 2004, Pages 50-53

  Klibanov, Olga M ^a,b,c   Raasch, Ralph H ^d   Rublein, John C ^b  

^a TEMPLE UNIVERSITY   (United States)

^b UNIVERSITY OF NORTH CAROLINA HOSPITALS   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d University of North Carolina   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; CREATININE; CYCLOSPORIN; DIPHENHYDRAMINE; DIURETIC AGENT; PARACETAMOL; PETHIDINE; TACROLIMUS; VORICONAZOLE; ANTIFUNGAL AGENT;

ACUTE KIDNEY FAILURE; ADULT; AGED; ANTIFUNGAL ACTIVITY; ARTICLE; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG FORMULATION; DRUG INDICATION; DRUG SAFETY; FEBRILE NEUTROPENIA; FUNGAL MENINGITIS; FUNGEMIA; HUMAN; KIDNEY FUNCTION; LUNG ASPERGILLOSIS; MAJOR CLINICAL STUDY; MORTALITY; MYCOSIS; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; BLOOD; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECT; FEMALE; KIDNEY; KIDNEY FUNCTION TEST; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; RETROSPECTIVE STUDY; UNITED STATES;

ADULT; AGED; AMPHOTERICIN B; ANTIFUNGAL AGENTS; CREATININE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; KIDNEY; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; MYCOSES; PHILADELPHIA; RETROSPECTIVE STUDIES;

EID: 1642568728     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/61.1.50     Document Type: Article

References (15)

1. Luber AD, Maa L, Lam M et al. Risk factors for amphotericin B-induced nephrotoxicity. J Antimicrob Chemother. 1999; 43:267-71.
2. Fisher MA, Talbot GH, Maislin G et al. Risk factors for amphotericin B-induced nephrotoxicity. Am J Med. 1989; 87:547-52.
3. Costa S, Nucci M. Can we decrease amphotericin nephrotoxicity? Curr Opin Crit Care. 2001; 7:379-83.
4. Wingard JR, Kubilis P, Lee L et al. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin Infect Dis. 1999; 29:1402-7.
5. Bates DW, Su L, Yu DT et al. Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis. 2001; 32:686-93.
6. Dupont B. Overview of the lipid formulations of amphotericin B. J Antimicrob Chemother. 2002; 49(suppl 1):31-6.
7. White MH, Bowden RA, Sandler ES et al. Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia. Clin Infect Dis. 1998; 27:296-302.
8. Walsh TJ, Finberg RW, Arndt C et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N EngI J Med. 1999; 340:764-71.
9. Anaisse EJ, Mattiuzzi GN, Miller CB et al. Treatment of invasive fungal infections in renally impaired patients with ampho-tericin B colloidal dispersion. Antimicrob Agents Chemother. 1998; 42:606-11.
10. Leenders AC, Daenen S, Jansen RL. Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections. Br J Haematol. 1998; 103:205-12.
11. Herbrecht R, Denning DW, Patterson TF et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002; 347:408-15.
12. Mora-Duarte J, Betts R, Rotstein C et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med. 2002; 347:2020-9.
13. Walsh TJ, Pappas P, Winston DJ et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med. 2002; 346:225-34.
14. Walsh TJ, Hiemenz JA, Seibel NL et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis. 1998; 26:1383-96.
15. Amphotericin B package insert. Huntington, NY: Pharma-Tek; 1998 Dec.